The POB NF team has been studying NF and NF-related tumors for over 25 years. In 2020, years of research culminated in the FDA approval of selumetinib, the first FDA approved drug for children 2 years and older with NF1 and NF1-related inoperable nerve tumors. Today, their research efforts continue to expand to improve the lives of children and adults with NF.

• Phase II Trial of the MEK inhibitor Selumetinib in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
• Phase II Trial of the MEK Inhibitor Selumetinib in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors 
• Phase I/II Study of the Cyclin Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas 
• Pilot Study of the MEK 1/2 Inhibitor for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
• Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement from Photographs of Subjects with Neurofibromatosis Type 1 on a Phase II Clinical Trial
• RASopathies Study: This study seeks to learn more about the development of tumors in individuals with a RASopathy (excluding NF1).